News

GeneDx and Prognos Health Announce Strategic Partnership to Help Rare Disease Patients More Rapidly Gain Access to Potential Treatment Options

Partnership allows commercial biopharma companies to leverage real-time data within comprehensive Prognos Marketplace to provide available treatment options for patients.

GeneDx to Report Second Quarter 2023 Financial Results on Tuesday, August 8, 2023

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will release financial results for the second quarter of 2023 after the market closes on Tuesday, August 8, 2023.

GeneDx to Present New Data on Urine Mitochondrial DNA Testing at the 2023 United Mitochondrial Disease Foundation’s Mitochondrial Medicine Symposium

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will present new data on urine mitochondrial DNA testing at the 2023 United Mitochondrial Disease Foundation’s (UMDF) Mitochondrial Medicine Symposium.